There were 1,065 press releases posted in the last 24 hours and 398,410 in the last 365 days.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, ADAP, PRVB, XM

NEW YORK, March 19, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Seagen Inc. SGEN's sale to Pfizer Inc. for $229.00 in cash per share. If you are a Seagen shareholder, click here to learn more about your rights and options.

Adaptimmune Therapeutics plc ADAP's merger with TCR² Therapeutics Inc. Under the terms of the agreement, TCR² stockholders will receive 1.5117 Adaptimmune ADS for each TCR² share. Following the closing of the transaction, Adaptimmune shareholders will own approximately 75% of the combined company. If you are a Adaptimmune shareholder, click here to learn more about your rights and options.

Provention Bio, Inc. PRVB's sale to Sanofi for $25.00 per share in cash. If you are a Provention shareholder, click here to learn more about your rights and options.

Qualtrics International Inc. XM's sale to Silver Lake for $18.15 per share in cash. If you are a Qualtrics shareholder, click here to learn more about your rights and options.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com


© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.